RG 002C0106
Alternative Names: RG-002C0106Latest Information Update: 29 Jul 2024
At a glance
- Originator Rigerna Therapeutics
- Class Drug conjugates; Galactosidases; Small interfering RNA
- Mechanism of Action Complement C3 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified